3,4-二乙氧基苯胺盐酸盐 | 4956-84-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 中文名称: 3,4-二乙氧基苯胺盐酸盐
• 英文名称: 3,4-Diethoxyaniline hydrochloride
• 英文别名: 3,4-diethoxyaniline;hydrochloride
• CAS: 4956-84-7
• 化学式: C10H16ClNO2
• mdl: MFCD00186134
• 分子量: 217.69
• InChiKey: TTYSYLOEQPQCGU-UHFFFAOYSA-N

物化性质

• 熔点：
  approximate 232℃(decomposition)
• 稳定性/保质期：

  在常温常压下保持稳定

计算性质

• 辛醇/水分配系数(LogP)：
  1.54
• 重原子数：
  14
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  44.5
• 氢给体数：
  2
• 氢受体数：
  3

安全信息

• 海关编码：
  2922299090

文献信息

• Kinase inhibitors
  申请人：Amgen Inc.

  公开号：US20040116388A1

  公开（公告）日：2004-06-17

  The invention relates to inhibitors of enzymes that bind to ATP or GTP and/or catalyze phosphoryl transfer, compositions comprising the inhibitors, and methods of using the inhibitors and inhibitor compositions. The inhibitors and compositions comprising them are useful for treating disease or disease symptoms. The invention also provides for methods of making phosphoryl transferase inhibitor compounds, methods of inhibiting phosphoryl transferase activity, and methods for treating disease or disease symptoms.

  这项发明涉及与ATP或GTP结合并/或催化磷酸转移的酶的抑制剂，包括这些抑制剂的组合物，以及使用这些抑制剂和抑制剂组合物的方法。这些抑制剂和包含它们的组合物对治疗疾病或疾病症状是有用的。该发明还提供了制备磷酸转移酶抑制剂化合物的方法，抑制磷酸转移酶活性的方法，以及治疗疾病或疾病症状的方法。
• TRIAZINE KINASE INHIBITORS
  申请人：Amgen Inc.,

  公开号：EP1218360A1

  公开（公告）日：2002-07-03
• US7074789B2
  申请人：——

  公开号：US7074789B2

  公开（公告）日：2006-07-11
• [EN] TRIAZINE KINASE INHIBITORS<br/>[FR] INHIBITEURS DE TRIAZINE KINASE
  申请人：KINETIX PHARMACEUTICALS INC

  公开号：WO2001025220A1

  公开（公告）日：2001-04-12

  The invention relates to inhibitors of formula (I) of enzymes that bind to ATP or GTP and/or catalyze phosphoryl transfer, compositions comprising the inhibitors, and methods of using the inhibitors and inhibitor compositions. The inhibitors and compositions comprising them are useful for treating disease or disease symptoms. The invention also provides for methods of making phosphoryl transferase inhibitor compounds, methods of inhibiting phosphoryl transferase activity, and methods for treating disease or disease symptoms. In formula (I), each R?1 and R2¿ is independently R?3; R8; NHR3; NHR5; NHR6; NR5R5; NR5R6; SR5; SR6; SR3; OR5; OR6; OR3; C(O)R3¿; heterocyclyl optionally substituted with 1-4 independent R4 on each ring; or C1-C10 alkyl substituted with 1-4 independent R?4; R3, R4, R5, R6, R8¿ are as defined in the application.